UK’s MHRA approves Moderna’s COVID-19 vaccine for emergency use

Moderna Inc. (NASDAQ: MRNA) said on Friday that it secured emergency use authorisation from the United Kingdom’s medicines’ regulator for its COVID-19 vaccine. It is the third vaccine that received a green light from Britain. The first two were AstraZeneca’s that the British-Swedish pharmaceutical giant developed in collaboration with the Oxford University, and Pfizer/BioNTech’s that showed over 90% efficacy in the late-stage trial. Moderna was reported about 1.5% up in premarket trading on Friday. At £86 per share, however, the stock is still trading significantly lower than the high of £124.91 per share in early December. The price action should